Hewlett Packard Enterprise Co — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Hewlett Packard Enterprise Co filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $34.30B | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $30.13B | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | $29.14B | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | $28.50B | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | $27.78B | Dec 22, 2023 |
| FY2020 | Oct 31, 2020 | $7.21B | Dec 10, 2020 |
| FY2020 | Jul 31, 2020 | $6.82B | Dec 10, 2020 |
| FY2020 | Apr 30, 2020 | $6.01B | Dec 10, 2020 |
| FY2020 | Jan 31, 2020 | $6.95B | Dec 10, 2020 |
| FY2020 | Oct 31, 2019 | $7.22B | Dec 10, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $57.00M | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $2.58B | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | $2.03B | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | $868.00M | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | $3.43B | Dec 22, 2023 |
| FY2022 | Oct 31, 2020 | ($322.00M) | Dec 8, 2022 |
| FY2021 | Oct 31, 2019 | $1.05B | Dec 10, 2021 |
| FY2020 | Oct 31, 2018 | $1.91B | Dec 10, 2020 |
| FY2019 | Oct 31, 2017 | $344.00M | Dec 13, 2019 |
| FY2018 | Oct 31, 2016 | $3.16B | Dec 12, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($437.00M) | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $2.19B | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | $2.09B | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | $782.00M | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | $1.13B | Dec 22, 2023 |
| FY2020 | Oct 31, 2020 | $145.00M | Dec 10, 2020 |
| FY2020 | Jul 31, 2020 | $12.00M | Dec 10, 2020 |
| FY2020 | Apr 30, 2020 | ($834.00M) | Dec 10, 2020 |
| FY2020 | Jan 31, 2020 | $348.00M | Dec 10, 2020 |
| FY2020 | Oct 31, 2019 | $460.00M | Dec 10, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $2.52B | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $2.25B | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | $2.35B | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | $2.05B | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | $1.98B | Dec 22, 2023 |
| FY2022 | Oct 31, 2020 | $1.87B | Dec 8, 2022 |
| FY2021 | Oct 31, 2019 | $1.84B | Dec 10, 2021 |
| FY2018 | Oct 31, 2018 | $439.00M | Dec 12, 2018 |
| FY2018 | Jul 31, 2018 | $434.00M | Dec 12, 2018 |
| FY2018 | Apr 30, 2018 | $402.00M | Dec 12, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $5.70B | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $4.87B | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | $5.16B | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | $4.94B | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | $4.93B | Dec 22, 2023 |
| FY2022 | Oct 31, 2020 | $4.62B | Dec 8, 2022 |
| FY2021 | Oct 31, 2019 | $4.91B | Dec 10, 2021 |
| FY2018 | Oct 31, 2018 | $1.22B | Dec 12, 2018 |
| FY2018 | Jul 31, 2018 | $1.20B | Dec 12, 2018 |
| FY2018 | Apr 30, 2018 | $1.23B | Dec 12, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $2.92B | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $4.34B | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | $4.43B | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | $4.59B | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | $5.87B | Dec 22, 2023 |
| FY2022 | Oct 31, 2020 | $2.24B | Dec 8, 2022 |
| FY2021 | Oct 31, 2019 | $4.00B | Dec 10, 2021 |
| FY2020 | Oct 31, 2018 | $2.96B | Dec 10, 2020 |
| FY2019 | Oct 31, 2017 | $1.34B | Dec 13, 2019 |
| FY2018 | Oct 31, 2016 | $5.06B | Dec 12, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $75.91B | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $71.26B | Dec 18, 2025 |
| FY2024 | Oct 31, 2023 | $57.15B | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | $57.12B | Dec 22, 2023 |
| FY2022 | Oct 31, 2021 | $57.70B | Dec 8, 2022 |
| FY2021 | Oct 31, 2020 | $54.02B | Dec 10, 2021 |
| FY2020 | Oct 31, 2019 | $51.80B | Dec 10, 2020 |
| FY2019 | Nov 1, 2018 | $20.47B | Dec 13, 2019 |
| FY2019 | Oct 31, 2018 | $55.49B | Dec 13, 2019 |
| FY2018 | Oct 31, 2017 | $61.41B | Dec 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Nov 1, 2018 | $14.28B | Dec 13, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $24.69B | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $24.82B | Dec 18, 2025 |
| FY2024 | Oct 31, 2023 | $21.18B | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | $19.86B | Dec 22, 2023 |
| FY2022 | Oct 31, 2021 | $19.97B | Dec 8, 2022 |
| FY2021 | Oct 31, 2020 | $16.05B | Dec 10, 2021 |
| FY2020 | Oct 31, 2019 | $17.10B | Dec 10, 2020 |
| FY2019 | Nov 1, 2018 | ($5.78B) | Dec 13, 2019 |
| FY2019 | Oct 31, 2018 | $21.24B | Dec 13, 2019 |
| FY2018 | Oct 31, 2017 | $23.47B | Dec 12, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $23.77B | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $18.09B | Dec 18, 2025 |
| FY2024 | Oct 31, 2023 | $17.99B | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | $17.40B | Dec 22, 2023 |
| FY2022 | Oct 31, 2021 | $18.31B | Dec 8, 2022 |
| FY2021 | Oct 31, 2020 | $18.02B | Dec 10, 2021 |
| FY2021 | Oct 31, 2019 | $18.31B | Dec 10, 2021 |
| FY2020 | Oct 31, 2018 | $17.54B | Dec 10, 2020 |
| FY2019 | Oct 31, 2017 | $17.52B | Dec 13, 2019 |
| FY2018 | Oct 31, 2016 | $16.09B | Dec 12, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($2.81B) | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | ($2.07B) | Dec 18, 2025 |
| FY2024 | Oct 31, 2023 | ($3.95B) | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | ($5.35B) | Dec 22, 2023 |
| FY2022 | Oct 31, 2021 | ($5.60B) | Dec 8, 2022 |
| FY2021 | Oct 31, 2020 | ($8.38B) | Dec 10, 2021 |
| FY2020 | Oct 31, 2019 | ($7.63B) | Dec 10, 2020 |
| FY2019 | Nov 1, 2018 | ($5.78B) | Dec 13, 2019 |
| FY2019 | Oct 31, 2018 | ($5.90B) | Dec 13, 2019 |
| FY2018 | Oct 31, 2017 | ($7.24B) | Dec 12, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $5.77B | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $14.85B | Dec 18, 2025 |
| FY2024 | Oct 31, 2023 | $4.27B | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | $4.16B | Dec 22, 2023 |
| FY2022 | Oct 31, 2021 | $4.00B | Dec 8, 2022 |
| FY2021 | Oct 31, 2020 | $4.23B | Dec 10, 2021 |
| FY2020 | Oct 31, 2019 | $3.75B | Dec 10, 2020 |
| FY2019 | Oct 31, 2018 | $4.88B | Dec 13, 2019 |
| FY2018 | Oct 31, 2017 | $9.58B | Dec 12, 2018 |
| FY2018 | Oct 31, 2016 | $12.99B | Dec 12, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $21.75B | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $17.66B | Dec 18, 2025 |
| FY2023 | Oct 31, 2023 | $11.69B | Dec 22, 2023 |
| FY2022 | Oct 31, 2022 | $11.94B | Dec 8, 2022 |
| FY2021 | Oct 31, 2021 | $12.46B | Dec 10, 2021 |
| FY2020 | Oct 31, 2020 | $14.80B | Dec 10, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 0 | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | 1 | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | 1 | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | 0 | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | 2 | Dec 22, 2023 |
| FY2020 | Oct 31, 2020 | 0 | Dec 10, 2020 |
| FY2020 | Jul 31, 2020 | 0 | Dec 10, 2020 |
| FY2020 | Apr 30, 2020 | 0 | Dec 10, 2020 |
| FY2020 | Jan 31, 2020 | 0 | Dec 10, 2020 |
| FY2019 | Oct 31, 2019 | 0 | Dec 13, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 0 | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | 1 | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | 1 | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | 0 | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | 2 | Dec 22, 2023 |
| FY2020 | Oct 31, 2020 | 0 | Dec 10, 2020 |
| FY2020 | Jul 31, 2020 | 0 | Dec 10, 2020 |
| FY2020 | Apr 30, 2020 | 0 | Dec 10, 2020 |
| FY2020 | Jan 31, 2020 | 0 | Dec 10, 2020 |
| FY2019 | Oct 31, 2019 | 0 | Dec 13, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 1.32B | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | 1.30B | Dec 18, 2025 |
| FY2024 | Oct 31, 2023 | 1.28B | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | 1.28B | Dec 22, 2023 |
| FY2022 | Oct 31, 2021 | 1.30B | Dec 8, 2022 |
| FY2021 | Oct 31, 2020 | 1.29B | Dec 10, 2021 |
| FY2020 | Oct 31, 2019 | 1.29B | Dec 10, 2020 |
| FY2019 | Oct 31, 2018 | 1.42B | Dec 13, 2019 |
| FY2018 | Oct 31, 2017 | 1.60B | Dec 12, 2018 |
| FY2017 | Oct 31, 2016 | 1.67B | Dec 15, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $684.00M | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $676.00M | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | $619.00M | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | $621.00M | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | $625.00M | Dec 22, 2023 |
| FY2022 | Oct 31, 2020 | $618.00M | Dec 8, 2022 |
| FY2021 | Oct 31, 2019 | $608.00M | Dec 10, 2021 |
| FY2020 | Oct 31, 2018 | $570.00M | Dec 10, 2020 |
| FY2019 | Oct 31, 2017 | $428.00M | Dec 13, 2019 |
| FY2018 | Oct 31, 2016 | $373.00M | Dec 12, 2018 |